Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-5-700 in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT07439653Phase 2Recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TORL-5-700 in non-Hodgkin lymphoma (NHL), sponsored by TORL BioTherapeutics. Started Mar 2026; status: recruiting.
02
Drugs
TORL-5-700
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07439653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439653.